The drugs developer cut sales guidance several times last year
Thursday 08 Mar 2018 Author: Lisa-Marie Janes

Last year was a difficult one for Hikma Pharmaceuticals (HIK) after it was forced to cut its sales guidance three times amid competitive challenges in its US generics business.

When Hikma reports 2017 full year results on 14 March, investors should look for details on how bad price and volume erosion for its generic drugs is expected to be in 2018.

The market should also dive into the results for updates on Hikma’s delayed launch of VR315, a generic version of GlaxoSmithKline’s (GSK) asthma treatment.

‹ Previous2018-03-08Next ›